Join        Login             Stock Quote
Top News :  

Global Stem Cell and Regenerative Medicine Index
By: Mike Havrilla   Tuesday, February 17, 2009 9:00 PM
KOOL also expects to enter the veterinary stem cell market under the Vantus brand and plans to launch Res-Q (a system for real-time processing of bone marrow and platelet rich plasma processing) during its fiscal 4Q09 as the Company hopes to achieve profitability during 2010.

Athersys (ATHX) collaborates with Angiotech Pharma (ANPI) to develop MultiStem for the treatment of damage caused by heart attacks, peripheral vascular disease, and strokes in addition to support for stem cell transplants.

Advanced Cell Technology (ACTC.PK) focuses on human embryonic and adult stem cell technology, with FDA approval to begin Phase 2 clinical trials for adult stem cell technologies, which are focused on cardiovascular disease and transplants.

International Stem Cell Corp (ISCO.OB) offers a unique technology technology, Parthenogenesis, which results in the creation of pluripotent (ability to differentiate into a variety of unique cell types) human stem cell lines from unfertilized human eggs. ISCO's technology has the potential to eliminate the rejection of stem cell transplants, avoid ethical issues by eliminating the need for fertilized embryos, and produce specialized cells for research applications.

Bioheart (BHRT) recently secured private financing commitments for up to $7M and recently announced a grant-funded study in Italy for the Bioheart A&C Bio Science Twin-Pulsatile Life Support System which is expected to be completed within just 45 days with the potential for $2.1M in contract sales if results are positive.

BHRT develops devices and biological therapeutics for the diagnosis, treatment, and monitoring of cardiovascular disease and heart failure. MyoCell is the Company's lead product candidate, which represents a muscle-derived stem cell therapy designed to improve heart function by replacing scar tissue with living cells to restore function.

Pluristem Therapeutics (PSTI) has developed a pipeline of product candidates derived from the human placenta and processed by the Company's PluriX bio-reactor as allogeneic (ready-to-use, non-personalized cell therapy products). The Company's pipeline includes product candidates for the treatement of peripheral artery disease (PLX-PAD), inflammatory bowel disease (PLX-IBD), multiple sclerosis (PLX-MS), bone marrow transplants (PLX-BMT), and ischemic stroke (PLX-STROKE).

HepaLife Technologies (HPLF.OB) cell-based technologies under development include an artificial liver device (HepaMate), in-vitro toxicology and pre-clinical drug testing platforms, and cell-culture based vaccine production methods for the manufacture of vaccines against H5N1 avian influenza and other viruses.

Stem Cell Innovations (SCLL.PK) is a develop-stage company focused on its C3A human liver cell line for the production of human serum proteins, including the clotting factors, Factor VIII and Factor IX, used by hemophiliacs to allow their blood to clot.

Isolagen (ILE) develops products for skin and tissue rejuvenation which are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne, and burn scars using a patient's own (autologous) fibroblast cells produced by its Isolagen Process for therapeutic and cosmetic medicine applications.

CellCyte Genetics (CCYG.OB) is a development-stage company focused on cell expansion and cell maintenance through the use of its patented bioreactor technology. The Company's therapeutic focus is on investigative collaborations to research and develop compounds to allow the safe and efficient non-invasive delivery of stem cells through the patient's own circulatory system to a diseased or damaged organ.

Cryo-Cell (CCEL.OB) offers cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood stem cells as a family cord blood stem cell bank and preserves the specimens in commercially available cryogenic storage equipment.

Brainstorm Cell Therapeutics (BCLI.OB) is a development-stage company focused on focused on using a patient's own bone marrow stem cells to generate neuron-like cells that provide treatment for Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS) and spinal cord injuries.

Opexa Therapeutics (OPXA) develops autologous (patient-derived) cell-based therapies to treat multiple sclerosis (MS), rheumatoid arthritis (RA), and diabetes based on the Company's T-cell and adult stem cell technologies. Opexa's lead product candidate is Tovaxin (a T-cell based therapeutic vaccine) for MS which is in a Phase 2b clinical trial.

Neostem (NBS) operates a commercial, autologous (patient-derived) adult stem cell bank for the pre-disease collection, processing and long-term storage of stem cells from adult donors that they can access for their own future medical treatment. The Company manages a network of adult stem cell collection centers throughout the U.S. and conducts research to identify and isolate rare stem cells from bone marrow.

Bio-Matrix Scientific Group (BMSN.OB) is a provider of disposable instruments and medical devices which are used in stem cell extraction and tissue transfer procedures and also operates cryogenic stem cell banking facilities.

Cord Blood America (CBAI.OB) preserves umbilical cord blood stem cells through a quick and non-invasive procedure at the time of birth. CBAI is focused on marketing initiatives to increase awareness of their services, which literally represent a once in a lifetime opportunity to collect and preserve cord blood stem cells which can be used in the future to treat dozens of conditions with the promise of even more medical breakthroughs with the FDA ruling to allow human stem cell testing and pending federal funding for stem cell research.

Stem Cell Therapeutics (Canada: SSS.V) is a regenerative medicine company that seeks to use drug-based treatments to stimulate a patient's existing stem cells in order to treat a variety of neurological conditions. The Company's pipeline includes lead compound NTx-265 for acute stroke, NTx-428 for traumatic brain injury, and NTx-488 for multiple sclerosis.

<< Previous Page12  
2/27/2009 8:20:49 AM
Project leader by prof. Dr. Shail k Sharma
I will like to receive comments.

Shail K Sharma
Rating: (3) (0)
Please send me regu;ar updates on Stem cells.
2/27/2009 8:22:38 AM
Project leader by prof. Dr. Shail k Sharma
Please send me regu;ar updates on Stem cells.
Rating: (2) (0)

Comments Closed


Related Press Releases
Popular Articles
Recent Articles by Mike Havrilla

Subscribe to Email Alerts rss feed or RSS feeds rss feed for articles from more than 800 contributors and press releases, SEC filings and full text news from thousands of sources.

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.